SGLT2 inhibitorsOlder adults are under-represented in trials, meaning the benefits and risks of glucose-lowering agents in this age group are unclear. The aim of this study was to assess the safety and effectiveness of sodium–glucose cotransporter 2 inhibitors (SGLT2i) in people with type 2 ...
To determine whether canagliflozin mediates its action solely through OxPhos inhibition, we compared its anti-proliferative activity to that of two specific OxPhos complex-I inhibitors, BAY-87-224347and IACS-01075948. At widely used doses, these agents significantly suppressed OCR in glycolytic rate bi...
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria. Circulation. 2024; 149(6): 450-462. DOI: 10.1161/...
SGLT2 inhibitorsBackground:Glycogen storage disease type Ib (GSD Ib) is a severe disorder of carbohydrate metabolism due to bi-allelic variants in SLC37A4. It is associated with neutropaenia and neutrophil dysfunction, which has recently been attributed to the accumulation of 1,5-anhydroglucitol-6...
SGLT, sodium glucose co-transporterSNS, sympathetic nervous systemT2DM, type 2 diabetes mellituserythropoetininflammationketonesRecent clinical trials have shown that sodium glucose co-transport 2 (SGLT2) inhibitors have dramatic beneficial cardiovascular outcomes. These include a reduced incidence of ...
Side effects of SGLT2 inhibitors therapy include urinary tract and genital infections. These drugs also have a diuretic effect, which can lead to the dehydration or hypotension. Some researches highlight the risks for bone fractures. SGLT2 inhibitors increase concentrations of phosphate in serum, ...
Exploring sodium glucose cotransporter (SGLT2) inhibitors with machine learning approach: A novel hope in anti-diabetes drug discoveryMd Moinul aSk Abdul Amin bPrabhat Kumar cUmesh Kumar Patil aAsmita Gajbhiye aTarun Jha bShovanlal Gayen d...
(1) Background: Sodium-glucose co-transporter-2 (SGLT-2) inhibitors constitute a novel drug class with remarkable cardiovascular benefits for patients with chronic heart failure (HF). Recently, this class has been utilized in acute HF as an additional treatment option to classic diuretics, which...